Tylenol use among women dropped after Trump tied it to autism

Core Insights - Tylenol use among pregnant women decreased significantly after President Trump's comments linking the medication to autism, with a 10% overall drop in prescriptions [1] - The most notable decline was a 16% reduction in prescriptions for pregnant women aged 15-44, peaking at a 20% drop in the third week following the announcement [1] - The study highlighted that thousands of women may have gone without necessary pain or fever treatment due to fear stemming from the President's statements [1] Company Impact - Kenvue Inc., the owner of the Tylenol brand, may face challenges due to the negative perception created by the association with autism, impacting sales and public trust [1] - The study indicated that despite the initial drop, prescriptions for Tylenol began to recover after several weeks, suggesting potential resilience in the brand's reputation [1] Industry Trends - The analysis revealed a concurrent increase in prescriptions for leucovorin, a treatment for children with autism, which rose by 71% during the same period, indicating a shift in treatment preferences among healthcare providers [1] - The findings underscore the broader implications of public health messaging and its influence on medication usage patterns, particularly in sensitive demographics like pregnant women [1]